Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07491445 by Revolution Medicines, Inc., with 900 participants planned, started 2026-03-09 and due to reach its primary completion in 2028-06. Interventions recorded: daraxonrasib, gemcitabine, nab-paclitaxel. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Revolution Medicines, Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Shares Revolution Medicines, Daraxonrasib.
- TrialStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Shares Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer